Fig. 1

Maximum intensity projection (MIP) of [⁶⁸Ga]Ga-DOTA-TOC (a) and [¹⁸F]SiTATE (b) PET of a 64-year-old male patient with Ileum NET (G1). The patient received Sandostatin LAR therapy between both PET scans (377 days between first and second scan), but the disease was considered stable. Blue arrows indicate comparably increased uptake of [¹⁸F]SiTATE compared to [⁶⁸Ga]Ga-DOTA-TOC or vice versa. Green arrows indicate some of the lesions, which were detected in the [¹⁸F]SiTATE PET, but not in the [⁶⁸Ga]Ga-DOTA-TOC PET